https://rheumatologydigest.org/tags/upadacitinib/Recent content in Upadacitinib on Rheumatology DigestHugoen-usSat, 04 Jul 2026 06:00:00 +0530https://rheumatologydigest.org/posts/select-switch-upa-vs-ada-ra/Sat, 04 Jul 2026 06:00:00 +0530https://rheumatologydigest.org/posts/select-switch-upa-vs-ada-ra/SELECT-SWITCH is the first double-blind RCT to test mechanism-of-action switching (to the JAK inhibitor upadacitinib) versus cycling to a second TNF inhibitor (adalimumab) after a first TNFi fails in RA. At 12 weeks, upadacitinib roughly doubled low-disease-activity rates and beat adalimumab on the primary endpoint and 4 of 5 ranked secondaries — though HAQ-DI function did not separate and safety was comparable.